Cargando…

Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open‐angle glaucoma and ocular hypertension

Latanoprostene bunod (LBN) ophthalmic solution 0.024% is a novel, once‐daily, nitric oxide‐donating prostaglandin analogue for the lowering of intraocular pressure (IOP) in patients with open‐angle glaucoma and ocular hypertension. The IOP‐lowering actions of LBN are mediated by dual mechanisms of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fingeret, Murray, Gaddie, Ian B, Bloomenstein, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Publishing Asia Pty Ltd 2019
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899723/ https://www.ncbi.nlm.nih.gov/pubmed/30614563 http://dx.doi.org/10.1111/cxo.12853

Ejemplares similares

Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
por: Hoy, Sheridan M.
Publicado: (2018)

Correction to: Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
por: Hoy, Sheridan M.
Publicado: (2018)

Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy
por: Addis, Victoria M, et al.
Publicado: (2018)

Latanoprostene Bunod 0.024% in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Meta-Analysis
por: Lo, Tzu-Chen, et al.
Publicado: (2022)

Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study
por: Kawase, Kazuhide, et al.
Publicado: (2016)

Retrospective Chart Review on Real-World Use of Latanoprostene Bunod 0.024% in Treatment-Naïve Patients with Open-Angle Glaucoma
por: Okeke, Constance O., et al.
Publicado: (2020)

Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects
por: Araie, Makoto, et al.
Publicado: (2015)

Critical evaluation of latanoprostene bunod in the treatment of glaucoma
por: Garcia, Giancarlo A, et al.
Publicado: (2016)

Use of Latanoprostene Bunod as Adjunctive Glaucoma Therapy in Refractory Glaucoma
por: Zhou, Benjamin, et al.
Publicado: (2022)

A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study
por: Weinreb, Robert N, et al.
Publicado: (2015)

Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma
por: Wang, Yulong, et al.
Publicado: (2020)

Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis
por: Harasymowycz, Paul, et al.
Publicado: (2022)

The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies
por: Cavet, Megan E., et al.
Publicado: (2018)

Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects
por: Malhotra, Ranjan P, et al.
Publicado: (2019)

Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension
por: Singh, Inder P., et al.
Publicado: (2020)

Safety of Fixed-Combination Bimatoprost 0.03%/Timolol 0.5% Ophthalmic Solution at 6 Months in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension
por: Sun, Xinghuai, et al.
Publicado: (2022)

Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
por: Araie, Makoto, et al.
Publicado: (2021)

A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension
por: Rhee, Douglas J, et al.
Publicado: (2008)

Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial
por: Day, Douglas G, et al.
Publicado: (2013)

Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension
por: Iester, Michele
Publicado: (2008)

Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial
por: Goldberg, Ivan, et al.
Publicado: (2014)

Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model
por: Meier, Edward J, et al.
Publicado: (2018)

The Role of Minimally Invasive Glaucoma Surgery Devices in the Management of Glaucoma
por: Fingeret, Murray, et al.
Publicado: (2018)

Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma
por: Walimbe, Tejaswini, et al.
Publicado: (2016)

Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review
por: Russo, Andrea, et al.
Publicado: (2008)

Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date
por: Dasso, Lily, et al.
Publicado: (2018)

Prospective Observational Post-marketing Study of Tafluprost 0.0015%/Timolol 0.5% Combination Ophthalmic Solution for Glaucoma and Ocular Hypertension: Short-Term Efficacy and Safety
por: Takagi, Yasutaka, et al.
Publicado: (2016)

Randomized, Double-Masked, Placebo-Controlled Dose Escalation Study of TAK-639 Topical Ophthalmic Solution in Subjects with Ocular Hypertension or Primary Open-Angle Glaucoma
por: Martin, Patrick, et al.
Publicado: (2020)

EHMTI-0024. The typical duration of migraine aura: a prospective diary-based study
por: Viana, M, et al.
Publicado: (2014)

A novel fixed-combination timolol-netarsudil-latanoprost ophthalmic solution for the treatment of glaucoma and ocular hypertension
por: Wang, Tao, et al.
Publicado: (2022)

Post-Marketing Surveillance of Levofloxacin 0.5% Ophthalmic Solution for External Ocular Infections
por: Kanda, Yoshiko, et al.
Publicado: (2012)

Ocular perfusion pressure and ophthalmic artery flow in patients with normal tension glaucoma
por: Samsudin, Amir, et al.
Publicado: (2016)

Travoprost in the management of open-angle glaucoma and ocular hypertension
por: Denis, Philippe, et al.
Publicado: (2007)

Comparative study of the ocular efficacy and safety of diclofenac sodium (0.1%) ophthalmic solution with that of ketorolac tromethamine (0.5%) ophthalmic solution in patients with acute seasonal allergic conjunctivitis
por: Dehar, Navdeep, et al.
Publicado: (2012)

An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy
por: Fung, Derrick S, et al.
Publicado: (2014)

Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial
por: McLaurin, Eugene, et al.
Publicado: (2018)

Preservative-Free versus Benzalkonium Chloride–Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial
por: Bacharach, Jason, et al.
Publicado: (2023)

In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
por: Sheppard, John D., et al.
Publicado: (2018)

Acute Angle-Closure Glaucoma Secondary to a Phakic Intraocular Lens, an Ophthalmic Emergency
por: Frost, Arian, et al.
Publicado: (2019)

Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
por: Pillunat, Lutz E, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_drl0oq4ifdmq2b58onblbkt927